Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. - Wikidata - awgldk - TriplyDB

Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.

Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.

http://www.wikidata.org/entity/Q39736462

about

Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretion Chaperones in hepatitis C virus infection Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection My Cousin, My Enemy: quasispecies suppression of drug resistance DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance.Treating hepatitis C infection by targeting the host.Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors.Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.Current and emerging antiviral treatments for hepatitis C infection Is there a role for cyclophilin inhibitors in the management of primary biliary cirrhosis?Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility Anti-HCV drugs in the pipeline.Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents.Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection Cyclophilins as modulators of viral replication.The role of immunophilins in viral infection.Cyclophilin inhibitors as a novel HCV therapy.Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus.Subtype specific differences in NS5A domain II reveals involvement of proline at position 310 in cyclosporine susceptibility of hepatitis C virus Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.

P2860

Q24303838-DD5ACEA3-1220-44DC-8935-2BB516292DA7 Q24308039-8805BCB5-8712-4EE3-8F27-6A7BCD3B1C57 Q26771251-A4AD50A1-588A-4B0D-A168-656A9DAC5A5F Q26779128-C92E41CE-0A78-418E-B5A5-3AC6C8D0E2B1 Q27468931-A77AB506-367E-4A2C-A6A8-6BFC5A786002 Q28076138-7621D8E4-A996-4538-B30B-5D13F6705403 Q28748683-1DAF0F8C-D5FF-4EC2-91BA-BC8128622A4E Q33424900-05DD0130-F925-48D2-BC04-79A58ACB5E31 Q35063336-9FF015F6-18DC-4621-9CD3-37515AE1533C Q35064369-05471823-08E4-4859-B8AB-95372DBA6A41 Q35650866-2FC5DDAC-37DC-407D-B4A9-B6B874A8616D Q35992555-6624FC9E-F06E-4503-A525-294BBE44DB25 Q36276866-44B66E4D-59EA-4F0E-A315-0B78C438A034 Q36363244-EB5D7526-C794-42A9-99F3-7E473E71F573 Q36579835-F1B47C48-0171-4228-9E5C-05F4B31626F2 Q36729900-25CED380-6505-4D97-BC13-6984FE623751 Q36807116-3B895656-664C-4150-81D6-437448FF185E Q37144087-EE62AA36-FB2E-40A5-BCCA-C076CBCC4F4B Q37177740-25AF9B71-D174-4040-9588-86115C9FEF31 Q37297666-55EF4BD2-6B79-4D07-8CF1-9D8A3EC3B267 Q37968485-D2129FF7-82F0-45B3-88D8-5A0485D61D29 Q38064282-93FB16F0-E42A-4AF8-AAB6-8C92A93B3331 Q38121470-99CC8FE0-9020-4DAC-A2C0-DCCEACA7B686 Q38274889-0B2995A3-170A-42AE-88D0-EB9AF7C45144 Q38615621-91D9471D-32E4-40AD-9AE1-DCE1E68FA023 Q38966123-E955ED4E-604E-44EF-892A-BE237B2FD912 Q39206099-83290A6F-A6D1-43B0-B12C-12694D531955 Q39244702-4EC1E08D-9287-418A-87F6-D7DB2AE492FC Q39313413-42FE7782-F464-4767-BE17-0FA5EE4FB911 Q39518505-B17D7AFB-DC46-4DBA-B96B-F6B070824032 Q39579921-3F56F5FE-D959-418A-A8CD-E95F7D1BE92A Q41843629-B843E954-AA60-436A-97B6-798A1E3E359D

P2860

Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.

http://www.wikidata.org/entity/Q39736462

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Mechanism of resistance of hep ...... stinct cyclophilin inhibitors.

@en

Mechanism of resistance of hep ...... stinct cyclophilin inhibitors.

@nl

type

label

Mechanism of resistance of hep ...... stinct cyclophilin inhibitors.

@en

Mechanism of resistance of hep ...... stinct cyclophilin inhibitors.

@nl

prefLabel

Mechanism of resistance of hep ...... stinct cyclophilin inhibitors.

@en

Mechanism of resistance of hep ...... stinct cyclophilin inhibitors.

@nl

P1433

Q39736462-65128B93-CD7D-4566-B612-DA85B82AE80E

P1476

Q39736462-F0ADD65F-5878-48B9-9F38-8C1EC15CF116

P2093

Q39736462-0F1E5CC1-D2C0-4B6E-841D-4041F3435863

Q39736462-1B936740-8754-46E2-BE47-49EC0822B831

Q39736462-6EA0F066-7E6C-4C2B-A0BA-7AA82BB335C5

Q39736462-819C115C-5CB6-4787-BB70-05D03DCBEA48

Q39736462-91AEC2A6-956B-4D74-B49A-080CA2BC5233

Q39736462-98F7B1D1-EAA7-41EB-8722-06FB2B70C4B3

Q39736462-ADEB43C8-05E9-4DFF-9FE2-5675A546589F

Q39736462-B3CB4E35-40A6-4CBA-88DC-D4F74AAE5A65

Q39736462-BF78836B-2685-491E-A091-0C8ECEEBD2F0

Q39736462-D6DEE0E4-B6BC-4258-986F-D6356129184D

P2860

Q39736462-016BB6A9-8794-42A2-A043-0407958D5207

Q39736462-0AC99A08-0400-4D4A-9516-9505CD96D365

Q39736462-2087B857-5D96-401B-81BD-07D8BFE92FA5

Q39736462-2CDA1AAF-C9A1-4100-9D14-EB59509AD4DF

Q39736462-445DE705-8C8B-40BE-B8F8-C081BB59D88D

Q39736462-53A61B34-1057-4DC3-8F5F-0A93C10B1DC9

Q39736462-5678A8B6-2024-4E15-9265-3B3941E7D29E

Q39736462-56E0C4AE-4C0B-477A-91AF-91BC6994B379

Q39736462-647CD149-04EA-4E64-8707-BFA265515C20

Q39736462-64E87C65-089E-4AC5-94E0-78C3D89AF7A9

P304

Q39736462-38D2F2AF-9281-4FAD-B49F-ABA390BF31B6

P31

Q39736462-07469BBE-16AC-4D58-97BF-52EDBB151D3E

P356

Q39736462-B8CBD94B-38A3-433B-99DE-6DCF3E27ED1F

P407

Q39736462-ED9C1A52-A8A3-4678-BD6E-0297E9FE7FC7

P433

Q39736462-4F536941-EA23-455D-BAA2-2F59899D1EE3

P478

Q39736462-08DC7456-A4F8-444B-A39B-A2FCE7320BF2

P577

Q39736462-68A5C9E4-3DED-4B23-9257-7F46C1365A80

P5875

Q39736462-6FC5F5B8-169B-4AC2-9BE5-CD39796544CA

P698

Q39736462-BE8C09BD-5D5D-4B71-B25B-BAEC11FB0D3E

P932

Q39736462-53CFB2B5-DEED-49A0-B8C1-E2F0900DAD0C

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Mechanism of resistance of hep ...... stinct cyclophilin inhibitors.

@en

P2093

Brigitte Wiedmann

http://www.w3.org/2001/XMLSchema#string

Danielle L Poulin

http://www.w3.org/2001/XMLSchema#string

Joanna E Mathy

http://www.w3.org/2001/XMLSchema#string

Kai Lin

http://www.w3.org/2001/XMLSchema#string

Leah J Anderson

http://www.w3.org/2001/XMLSchema#string

Roger Fujimoto

http://www.w3.org/2001/XMLSchema#string

Shejin Zhu

http://www.w3.org/2001/XMLSchema#string

Sue Ma

http://www.w3.org/2001/XMLSchema#string

Teresa Compton

http://www.w3.org/2001/XMLSchema#string

Xiaoling Puyang

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase

Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft

Diverse Effects of Cyclosporine on Hepatitis C Virus Strain Replication

NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon

Visualization of Double-Stranded RNA in Cells Supporting Hepatitis C Virus RNA Replication

Combinations of Cyclophilin Inhibitor NIM811 with Hepatitis C Virus NS3-4A Protease or NS5B Polymerase Inhibitors Enhance Antiviral Activity and Suppress the Emergence of Resistance

Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B

Efficient initiation of HCV RNA replication in cell culture

Epidemiology of hepatitis C: geographic differences and temporal trends

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

P304

1981-1987

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01236-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41532304

http://www.w3.org/2001/XMLSchema#string

P698

20176894

http://www.w3.org/2001/XMLSchema#string

P932

2863619

http://www.w3.org/2001/XMLSchema#string